Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Receivables - Net: 2011-2025

Historic Receivables - Net for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to $6.9 million.

  • Enanta Pharmaceuticals' Receivables - Net rose 3.55% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 3.55%. This contributed to the annual value of $6.9 million for FY2025, which is 3.55% up from last year.
  • As of FY2025, Enanta Pharmaceuticals' Receivables - Net stood at $6.9 million, which was up 3.55% from $6.6 million recorded in FY2024.
  • Enanta Pharmaceuticals' Receivables - Net's 5-year high stood at $23.6 million during FY2021, with a 5-year trough of $6.6 million in FY2024.
  • Its 3-year average for Receivables - Net is $7.4 million, with a median of $6.9 million in 2025.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Receivables - Net slumped by 57.60% in 2023, and later grew by 3.55% in 2025.
  • Yearly analysis of 5 years shows Enanta Pharmaceuticals' Receivables - Net stood at $23.6 million in 2021, then fell by 13.82% to $20.3 million in 2022, then tumbled by 57.60% to $8.6 million in 2023, then dropped by 22.85% to $6.6 million in 2024, then climbed by 3.55% to $6.9 million in 2025.